This company has been marked as potentially delisted and may not be actively trading. Can B (CANB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesTrendsBuy This Stock CANB vs. MEDS, BIMI, HCWB, ATNF, FRTX, NRBO, IMCC, BGLC, QNRX, and KTTAShould you be buying Can B stock or one of its competitors? The main competitors of Can B include TRxADE HEALTH (MEDS), BIMI (BIMI), HCW Biologics (HCWB), 180 Life Sciences (ATNF), Fresh Tracks Therapeutics (FRTX), NeuroBo Pharmaceuticals (NRBO), IM Cannabis (IMCC), BioNexus Gene Lab (BGLC), Quoin Pharmaceuticals (QNRX), and Pasithea Therapeutics (KTTA). These companies are all part of the "medical" sector. Can B vs. Its Competitors TRxADE HEALTH BIMI HCW Biologics 180 Life Sciences Fresh Tracks Therapeutics NeuroBo Pharmaceuticals IM Cannabis BioNexus Gene Lab Quoin Pharmaceuticals Pasithea Therapeutics TRxADE HEALTH (NASDAQ:MEDS) and Can B (NASDAQ:CANB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Do insiders & institutionals believe in MEDS or CANB? 5.7% of TRxADE HEALTH shares are held by institutional investors. Comparatively, 6.1% of Can B shares are held by institutional investors. 48.4% of TRxADE HEALTH shares are held by insiders. Comparatively, 11.4% of Can B shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better earnings & valuation, MEDS or CANB? Can B has lower revenue, but higher earnings than TRxADE HEALTH. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTRxADE HEALTH$7.45M0.27-$17.84MN/AN/ACan B$2.16M0.57-$9.74MN/AN/A Is MEDS or CANB more profitable? TRxADE HEALTH has a net margin of -149.81% compared to Can B's net margin of -1,238.33%. Can B's return on equity of 0.00% beat TRxADE HEALTH's return on equity.Company Net Margins Return on Equity Return on Assets TRxADE HEALTH-149.81% -196.79% -112.21% Can B -1,238.33%N/A -218.65% Does the media favor MEDS or CANB? In the previous week, TRxADE HEALTH and TRxADE HEALTH both had 1 articles in the media. TRxADE HEALTH's average media sentiment score of 0.00 beat Can B's score of -0.14 indicating that TRxADE HEALTH is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TRxADE HEALTH 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Can B 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, MEDS or CANB? TRxADE HEALTH has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500. Comparatively, Can B has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. SummaryTRxADE HEALTH beats Can B on 6 of the 10 factors compared between the two stocks. Get Can B News Delivered to You Automatically Sign up to receive the latest news and ratings for CANB and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANB vs. The Competition Export to ExcelMetricCan BDrugs, proprietaries, & sundries IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22M$2.79M$5.53B$9.05BDividend YieldN/AN/A5.24%4.03%P/E RatioN/AN/A27.5020.21Price / Sales0.570.27421.02118.64Price / CashN/AN/A36.8958.07Price / Book-0.053.228.045.67Net Income-$9.74M-$17.84M$3.18B$249.13M Can B Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANBCan BN/A$0.01-26.6%N/A+34.5%$1.22M$2.16M0.0016News CoverageGap DownMEDSTRxADE HEALTHN/A$1.04+11.2%N/A-91.7%$1.46M$7.45M0.0050News CoverageBIMIBIMIN/A$0.00flatN/AN/A$1K$12.63M0.00520HCWBHCW Biologics4.3401 of 5 stars$3.75-5.3%$35.00+833.3%-83.1%$5.71M$2.57M-0.1640ATNF180 Life Sciences0.6066 of 5 stars$0.89-4.1%N/A-44.5%$5.63MN/A0.007FRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+0.6%$5.59M$10.06M-0.6620NRBONeuroBo PharmaceuticalsN/A$0.64+2.1%N/A-85.2%$5.54MN/A0.0010News CoverageGap UpIMCCIM Cannabis0.3632 of 5 stars$2.70+8.9%N/A+3.7%$5.54M$39.44M-4.22340Positive NewsBGLCBioNexus Gene Lab0.4411 of 5 stars$11.14+262.9%N/A+33.5%$5.52M$9.51M0.0030Gap DownHigh Trading VolumeQNRXQuoin Pharmaceuticals0.5382 of 5 stars$9.23flatN/A-55.2%$5.43MN/A-0.194KTTAPasithea Therapeutics1.0248 of 5 stars$0.73+1.8%N/A-85.5%$5.37MN/A-0.073 Related Companies and Tools Related Companies MEDS Competitors BIMI Competitors HCWB Competitors ATNF Competitors FRTX Competitors NRBO Competitors IMCC Competitors BGLC Competitors QNRX Competitors KTTA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CANB) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can B Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can B With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANB Stock Alerts